相关实验视频

Updated: Jun 21, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

疾病预防控制中心20的诊断价值,用于肺腺癌的恶性多流

Yulan Liu¹, Liping Wu², Jinrong Chen¹

¹Department of Pathology, The Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, No. 4, North Fourth Section, Second Ring Road, Chengdu, 610051, Sichuan Province, China.

Scientific reports

|March 3, 2026

概括

细胞分裂循环蛋白20 (CDC20) 显示出作为肺腺癌 (LUAD) 检测在多叶流液中的新生物标志物的潜力. 这种侵入性较小的方法有助于早期诊断和 LUAD 的病理评估.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
细胞病理学细胞病理学

背景情况:

肺腺癌 (LUAD) 呈现出诊断挑战,特别是在恶性多叶流血 (MPE) 的晚期阶段.
胸腔溢液的细胞学检查为诊断LUAD提供了比肺活检更少侵入性的替代方案.
新型生物标志物对于改善在多流样本中检测LUAD至关重要.

研究的目的:

识别和验证肺腺癌 (LUAD) 的新细胞学生物标志物在恶性多流液 (MPE) 中.
评估细胞分裂周期蛋白20 (CDC20) 作为LUAD生物标记物的诊断潜力.

主要方法:

使用Gepia数据库进行差异基因表达分析,以确定候选生物标记物.
通过免疫组织化学分析92个LUAD和相邻的正常组织中的CDC20,TTF-1和NapsinA表达.
在从30个LUAD和30个非新生病例的肺部溢出细胞学中检测到CDC20的免疫组织化学检测.

主要成果:

细胞分裂周期蛋白20 (CDC20) 被确定为LUAD中差异表达的基因.
在LUAD组织中观察到增加的CDC20表达,与瘤大小,T分类和膜入侵相关.
在流细胞学中,CDC20的表达与TTF-1和NapsinA显示一致,这表明它在MPE诊断中的实用性.

结论:

疾病预防控制中心20在组织和肺部溢液样本中显示出作为肺腺癌 (LUAD) 诊断生物标志物的显著潜力.
这些发现突显了CDC20在恶性多流液 (MPE) 细胞学的病理诊断中的价值.
这一发现有助于推进LUAD的少入侵诊断策略.

关键词:

细胞分裂周期蛋白 20 细胞分裂周期蛋白肺部腺癌瘤是肺部腺癌.病理诊断病理诊断病理诊断恶性多叶膜溢出恶性多叶膜溢出

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

相关概念视频

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...